[18F]FDG PET/CT imaging of colorectal cancer: a pictorial review

Published on Mar 1, 2010in Postgraduate Medical Journal1.911
· DOI :10.1136/PGMJ.2009.079087
Fahmid U. Chowdhury18
Estimated H-index: 18
,
Nehal Shah1
Estimated H-index: 1
+ 1 AuthorsKevin M. Bradley28
Estimated H-index: 28
Sources
Abstract
Integrated positron emission tomography/CT (PET/CT) with 2-[ 18 F]fluoro-2-deoxy-d-glucose (FDG) is a hybrid imaging modality which has recently become established in the staging, restaging and therapy response assessment of oncology patients. FDG PET/CT has several recognised applications in colorectal cancer (CRC) imaging including preoperative evaluation of apparently limited metastatic disease, detection of disease recurrence, clarification of equivocal lesions at initial staging, investigation of unexplained rising tumour markers, and incidental detection of occult primary colonic tumours. With a constantly advancing body of evidence and increasing availability, applications of PET/CT in CRC are likely to emerge in therapy response assessment, radiotherapy planning, use of novel tracers and ‘one-stop’ imaging techniques such as iodinated contrast-enhanced PET/CT. With the use of illustrative clinical examples, this article reviews the utility of FDG PET/CT in the management of CRC, discussing its role and limitations in the multimodality imaging of these patients.
📖 Papers frequently viewed together
74 Citations
63 Citations
1 Author (Max Lonneux)
7 Citations
References56
Newest
#1R. A. Herbertson (Ludwig Institute for Cancer Research)H-Index: 9
#2Andrew Scarsbrook (St James's University Hospital)H-Index: 29
Last. Andrew M. Scott (Ludwig Institute for Cancer Research)H-Index: 87
view all 5 authors...
Positron-emission tomography–computed tomography (PET/CT) is rapidly being integrated into the imaging pathways of several different tumour types, most frequently using the glucose analogue 2- [ 18 F]-fluoro-2-deoxy-d-glucose (FDG). Integrated FDG-PET/CT combines functional and anatomical imaging to improve sensitivity and specificity of tumour detection. The aim of this article is to review the established, emerging, and future roles of FDG-PET/CT in the management of patients with colorectal c...
56 CitationsSource
#1Elizabeth A. Eisenhauer (Queen's University)H-Index: 69
#2P. Therasse (GSK: GlaxoSmithKline)H-Index: 13
Last. Jaap Verweij (Erasmus University Medical Center)H-Index: 125
view all 16 authors...
Abstract Background Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to th...
16.4k CitationsSource
#1Fahmid U. ChowdhuryH-Index: 18
#2Kevin M. BradleyH-Index: 28
Last. Fergus V. GleesonH-Index: 58
view all 3 authors...
Integrated positron-emission tomography/computed tomography (PET/CT) with 2-[fluorine-18] fluoro-2-deoxy- d -glucose (FDG) is now established in the management of oncology patients. With increasing availability and a constantly advancing body of evidence, the role of FDG PET/CT in oesophageal cancer is set to expand to include initial staging, assessment of disease response, therapy planning, and detection of disease recurrence. This article reviews the utility of FDG PET/CT in the management of...
51 CitationsSource
#1S. Dighe (The Royal Marsden NHS Foundation Trust)H-Index: 6
#2Ian SwiftH-Index: 14
Last. Gina Brown (The Royal Marsden NHS Foundation Trust)H-Index: 79
view all 3 authors...
Computer tomography (CT) has been the principal investigation in the staging of colon cancers. The information obtained with routine CT has been limited to identifying the site of the tumour, size of the tumour, infiltration into surrounding structures and metastatic spread. The Foxtrot trial National Cancer Research Institute (NCRI) has been specifically designed to evaluate the efficacy of neoadjuvant treatment in colon cancers by using preoperative chemotherapy with or without an anti-Epiderm...
50 CitationsSource
#1Shiva Badiee (UCSF: University of California, San Francisco)H-Index: 3
#2Benjamin L. Franc (UCSF: University of California, San Francisco)H-Index: 26
Last. Fergus V. Coakley (UCSF: University of California, San Francisco)H-Index: 63
view all 6 authors...
OBJECTIVE. The purpose of our study was to investigate the role of IV iodinated contrast material in the evaluation of hepatic metastases at 18F-FDG PET/CT.MATERIALS AND METHODS. We retrospectively identified 39 patients (25 men and 14 women) with suspected isolated hepatic metastases from colorectal cancer who underwent FDG PET/CT. The CT protocol included acquisition of unenhanced and multiphase contrast-enhanced CT images through the liver. At two separate sittings, four readers (two radiolog...
28 CitationsSource
#1Hilmar KuehlH-Index: 30
#2Gerald AntochH-Index: 69
Last. Andreas BockischH-Index: 77
view all 9 authors...
Abstract Purpose Morphologic imaging after radiofrequency ablation (RFA) of liver metastases is hampered by rim-like enhancement in the ablation margin, making the identification of local tumor progression (LTP) difficult. Follow-up with PET/CT is compared to follow-up with PET alone and MRI after RFA. Methods and materials Sixteen patients showed 25 FDG-positive colorectal liver metastases in pre-interventional PET/CT. Post-interventional PET/CT was performed 24 h after ablation and was repeate...
96 CitationsSource
The management of advanced colorectal cancer has changed dramatically during the last decade. By redefining resectability, and with the use of modern chemotherapy, nearly 10% of unresectable patients are now alive 5 years after diagnosis, and, overall, 20% are alive at 5 years when the combined results of surgery and chemotherapy are considered. These achievements are not reflected in the current staging, which categorizes all disease spread beyond the lymph node basin of the primary tumor as un...
7 CitationsSource
#1Brian M. Wolpin (Harvard University)H-Index: 64
#2Robert J. Mayer (Harvard University)H-Index: 126
Colorectal cancer is the fourth most common noncutaneous malignancy in the United States and the second most frequent cause of cancer-related death. Over the past 12 years, significant progress has been made in the systemic treatment of this malignant condition. Six new chemotherapeutic agents have been introduced, increasing median overall survival for patients with metastatic colorectal cancer from less than 9 months with no treatment to approximately 24 months. For patients with stage III (ly...
513 CitationsSource
#1Laura Lavinia Travaini (IEO: European Institute of Oncology)H-Index: 18
#2Giuseppe Trifirò (IEO: European Institute of Oncology)H-Index: 28
Last. Giovanni Paganelli (IEO: European Institute of Oncology)H-Index: 78
view all 11 authors...
Purpose Focal metastasis may be treated with radiofrequency ablation (RFA), a low invasive method yet limited by the lack of direct evidence of radicality of treatment. We, hereby, aimed at assessing the role of positron emission tomography–computed tomography (PET/CT) with fluoride radiolabeled deoxy-glucose ([18F]FDG) in RFA treatment success evaluation and early diagnosis of local relapse of liver metastasis after RFA procedure.
54 CitationsSource
#1Jan SoykaH-Index: 16
Last. Thomas F. HanyH-Index: 57
view all 8 authors...
18 F-FDG PET/CT has gained wide acceptance for evaluation of recurrent colorectal carcinoma. However in clinical practice, contrast-enhanced CT (ceCT) is still the first-line restaging tool. The aim of this study was to investigate the value of contrast-enhanced PET/CT (cePET/CT) as a first-line restaging tool with a special focus on the importance of the use of intravenous contrast. Methods: Fifty-four patients (17 women, 37 men; mean age, 60.3 y), referred for restaging of colorectal carcinoma...
96 CitationsSource
Cited By25
Newest
#1Waleed M. Hetta (Ain Shams University)H-Index: 4
#2Gamal Niazi (Ain Shams University)H-Index: 4
Last. Mohammed H. Abdelbary (Cairo University)
view all 3 authors...
The study shows the role of PET/CT in monitoring response to therapy in colorectal cancer as well as detection of loco-regional recurrence and metastatic deposits hence guiding the clinician to the proper management strategy. Sixty patients (41male and 19 female) were included in our study. All patients are pathologically proven colorectal cancer. They had undergone 18F-FDG PET/CT for follow up post-therapeutic (operative, and/or chemotherapy and/or radiotherapy) follow up for metastatic or recu...
Source
#1Talaat A. HassanH-Index: 3
#2Ahmed A. BazH-Index: 2
Abstract Background: One of the most common cancers, colorectal cancer accounts for several tumor-related mortalities; its high recurrence rates either as a local recurrence of the disease or as a distant metastatic disease (up to 35-40%) have been reported in the treated patients within the first two years following surgery. There has been heated debate over the modality of choice for imaging of the recurrent colorectal cancer. Aim of Study: This study investigates the diagnostic performance of...
Source
Last. Andreas K. Buck (University of Würzburg)H-Index: 58
view all 5 authors...
Contrast-enhanced CT, magnetic resonance imaging and endoscopic ultrasound represent the mainstay imaging modalities for T-staging of GI-tract malignancies and radiotherapy planning. PET and PET/CT have a complementary role. In esophageal carcinoma and cancer of the esophagogastric junction, PET imaging improves definition of the local tumor extent and detection of involved locoregional lymph nodes, leading to enhanced target volume definition. Consequently, addition of functional imaging leads ...
Source
#1Bing Hao (Ha Tai: Xiamen University)H-Index: 4
#2Long Zhao (Ha Tai: Xiamen University)H-Index: 5
Last. Long Sun (Ha Tai: Xiamen University)H-Index: 8
view all 13 authors...
Background To investigate whether PET/CT-guided bone marrow biopsy adds complementary information for evaluation of bone marrow involvement (BMI) in newly diagnosed lymphomas.
4 CitationsSource
#1Jun Huang (SYSU: Sun Yat-sen University)H-Index: 18
#2Liang Huang (SYSU: Sun Yat-sen University)H-Index: 7
Last. Meijin Huang (SYSU: Sun Yat-sen University)H-Index: 17
view all 11 authors...
Purpose The prognostic value of the tumor-to-liver uptake ratio (TLR) from 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F–FDG-PET/CT) in the early stage of colorectal cancer (CRC) is unclear. Notably, some stage IIA CRC patients experience early recurrence even after curative resection and might benefit from neoadjuvant or adjuvant chemotherapy. This study aims to evaluate whether elevated TLR from 18F–FDG-PET/CT can predict poor prognosis in stage IIA CRC patient...
18 CitationsSource
#1Mahila Ferrari (IEO: European Institute of Oncology)H-Index: 29
#2Laura Lavinia Travaini (IEO: European Institute of Oncology)H-Index: 18
Last. Marta Cremonesi (IEO: European Institute of Oncology)H-Index: 42
view all 13 authors...
Abstract 18 F-fluorodeoxyglucose PET/CT ( 18 F-FDG-PET/CT) is widely applied in oncology for disease staging, assessment of therapy response, relapse diagnosis, follow-up and target volume delineation. In particular, it can detect early response during chemoradiotherapy (interim) because functional modifications usually precede morphological ones. This ability is crucial to the radiation oncologist for the management of patients, to avoid persisting with ineffective therapy − often leading toxic...
6 CitationsSource
#1Zhonglin Liu (UA: University of Arizona)H-Index: 14
#2Brian D. GrayH-Index: 14
Last. James M. Woolfenden (UA: University of Arizona)H-Index: 26
view all 14 authors...
Abstract Molecular probes capable of detecting colorectal cancer (CRC) are needed for early CRC diagnosis. The objective of this study was to characterize c[CTPSPFSHC]OH (TCP-1), a small peptide derived from phage display selection, for targeting human CRC xenografts using technetium-99m ( 99m Tc)-labeled TCP-1 and fluorescent cyanine-7 (Cy7)-labeled form of the peptide (Cy7-TCP-1). 99m Tc-TCP-1 was generated by modifying TCP-1 with succinimidyl-6-hydrazino-nicotinamide (S-HYNIC) followed by rad...
6 CitationsSource
#1Parunya Chaiyawat (Chulabhorn Graduate Institute)H-Index: 10
#2Pukkavadee Netsirisawan (Chulabhorn Graduate Institute)H-Index: 6
Last. Voraratt Champattanachai (Chulabhorn Research Institute)H-Index: 13
view all 4 authors...
Increasing glucose consumption is thought to provide an evolutionary advantage to cancer cells. Alteration of glucose metabolism in cancer influences various important metabolic pathways including the hexosamine biosynthesis pathway (HBP), a relatively minor branch of glycolysis. Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), an end product of HBP, is a sugar substrate used for classical glycosylation and O-GlcNAcylation, a post-translational protein modification implicated in a wide rang...
22 CitationsSource
#1Rasmus K Petersen (OUH: Odense University Hospital)H-Index: 1
#2Søren Hess (OUH: Odense University Hospital)H-Index: 19
Last. Poul Flemming Høilund-Carlsen (OUH: Odense University Hospital)H-Index: 36
view all 4 authors...
FDG-PET/CT is rarely used for initial staging of patients with colorectal cancer (CRC). Surgical resection of primary tumor and isolated metastases may result in long-term survival or presumed cure, whereas disseminated disease contraindicates operation. We analyzed a retrospective material to elucidate the potential value of FDG-PET/CT for staging of CRC. Data were retrieved from 67 consecutive patients (24-84 years) with histopathologically proven CRC who had undergone FDG-PET/CT in addition t...
22 Citations
#1Florent Tixier (French Institute of Health and Medical Research)H-Index: 19
#2Ashley M. GrovesH-Index: 48
Last. Dimitris Visvikis (French Institute of Health and Medical Research)H-Index: 55
view all 7 authors...
METHODS: Thirty patients with proven colorectal cancer prospectively underwent integrated 18F-FDG PET/DCE-CT to assess the metabolic-flow phenotype. Both CT blood flow parametric maps and PET images were analyzed. Correlations between PET heterogeneity and perfusion CT were assessed by Spearman's rank correlation analysis. RESULTS: Blood flow visualization provided by DCE-CT images was significantly correlated with 18F-FDG PET metabolically active tumor volume as well as with uptake heterogeneit...
30 CitationsSource